Cellular and T cell engager Immunotherapy
Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN)
Rakesh Popat, MD, PhD
Consultant Haematologist & Associate Professor
University College London Hospitals NHS Foundation Trust
LONDON, England, United Kingdom